Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOZART
2023-506049-52-00Phase 2Authorised
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Oct 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of mosunetuzumab and zanubrutinib in follicular lymphoma (FL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Complete response rate at end of combination therapy. Planned start Oct 2024; status: authorised.
02
Drugs
mosunetuzumabzanubrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-506049-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506049-52-00.